Stocktoria
INSMED Inc INSM
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1991-02-15
INSMED Inc financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $606.4M | $363.7M | $305.2M | $245.4M | $188.5M |
| R&D expense | $771.1M | $598.4M | $571.0M | $397.5M | $272.7M |
| SG&A expense | $701.2M | $461.1M | $344.5M | $265.8M | — |
| Operating income | -$1.2B | -$878.3M | -$709.6M | -$457.3M | -$375.1M |
| Interest expense | $83.8M | $84.9M | $81.7M | $26.4M | $40.5M |
| Income tax | $5.0M | $3.7M | $2.6M | $1.4M | -$1.8M |
| Net income | -$1.3B | -$913.8M | -$749.6M | -$481.5M | -$434.7M |
| EPS (diluted) | $-6.42 | $-5.57 | $-5.34 | $-3.91 | $-3.88 |
| Operating cash flow | -$935.0M | -$683.9M | -$536.2M | -$400.4M | -$363.3M |
| Free cash flow | -$967.6M | -$705.8M | -$549.5M | -$410.3M | -$370.6M |
| Cash & equivalents | $510.4M | $555.0M | $482.4M | $1.1B | $716.8M |
| Inventory | $132.1M | $98.6M | $83.2M | $69.9M | $67.0M |
| Total assets | $2.3B | $2.0B | $1.3B | $1.7B | $1.2B |
| Total liabilities | $1.5B | $1.7B | $1.7B | $1.6B | $833.0M |
| Shareholders' equity | $739.0M | $285.4M | -$331.9M | $88.0M | $410.5M |
Source: SEC EDGAR filings · CIK 0001104506 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.